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Abstract
Antioxidant and antifibrotic properties of colchicine were investigated in the carbon tetrachloride (CCl4) rat model. (1)
The protective effect of colchicine pretreatment on CCl4 induced oxidant stress was examined in rats subsequently receiving a
single lethal dose of CCl4. Urinary 8-isoprostane, kidney and liver malondialdehyde and kidney glutathione levels increased
following CCl4 treatment, but only the rise in kidney malondialdehyde was significantly inhibited by colchicine pretreatment.
Serum total antioxidant levels were significantly higher in the colchicine pretreatment group. (2) The long term effects of
colchicine treatment on CCl4 induced liver damage were investigated using liver histology and biochemical markers
(hydroxyproline and type III procollagen peptide). Co-administration of colchicine with sub-lethal doses of CCl4 over 10
weeks did not prevent progression to cirrhosis. However, rats made cirrhotic with repeated CCl4 challenge and subsequently
treated with colchicine for 12 months, all showed histological regression of cirrhosis. (3) The antioxidant effect of colchicine
in vitro was evident only at very high concentrations compared to other plasma antioxidants. In summary, colchicine has
only weak antioxidant properties, but does afford some protection against oxidative stress ; more importantly, long term
treatment with this drug may be of value in producing regression of established cirrhosis. ß 2000 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Although colchicine is an ancient drug, ¢rst re-
corded by the ancient Greeks, its use in liver disease
is comparatively recent. Diegelmann ¢rst discovered
the anti¢brotic properties of the drug during in vitro
experiments in 1972 [1]. In subsequent animal experi-
ments, it was noted that co-administration of colchi-
cine ameliorated both acute [2] and chronic liver
damage [3,4] in CCl4 treated rats. Pretreatment
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with colchicine also mitigated galactosamine medi-
ated injury [5] and reduced ¢brosis after bile duct
ligation [6].
These studies have resulted in considerable interest
in colchicine as a therapeutic agent in chronic liver
disease. In one clinical trial, in patients with alco-
holic and post-hepatitic cirrhosis on long term col-
chicine treatment, median survival for the colchicine
treatment group was 11.5 years compared to 3.5
years in the placebo group. Histological regression
was also noted in 9/30 patients from the colchicine
group compared to none from the placebo treated
group [7]. However, in other trials, the majority of
which were conducted in patients with primary bili-
ary cirrhosis, the drug did not appear to have any
signi¢cant e¡ect on symptoms, clinical features or
liver histology [8,9]. The e¡ect on survival also ap-
peared to be either less dramatic [10] or not apparent
[9]. In view of this discrepancy between clinical and
animal studies, we considered that the animal model
should be re-examined, to establish whether the ther-
apeutic bene¢ts of this drug have been overestimated
and to investigate possible mechanisms of action,
particularly in those areas which have not previously
been examined in depth.
While colchicine is known to have an anti-tubulin
action and to inhibit mitosis, its possible bene¢cial
e¡ects in liver disease have been ascribed to a wide
range of properties. These include an anti-in£amma-
tory action, inhibition of lipid peroxidation [11],
membrane stabilisation [12], and reduction in cyto-
chrome P-450 levels [13]. In acute CCl4 injury, col-
chicine pretreatment was shown to blunt, in a dose
dependent manner, the normal rise in hepatic malon-
dialdehyde (MDA) concentration [14], and the rise in
membrane bound adenyl cyclase and serum enzyme
levels [2,15]. Alterations in membrane cholesterol-
phospholipid ratio and in levels of membrane bound
enzymes (NaK- and Ca2-dependent adenosine
triphosphatase and adenyl cyclase), were also noted
following acute CCl4 injury and were either pre-
vented or reversed by colchicine treatment [12,15].
It has been proposed that colchicine treatment, by
limiting acute CCl4 induced damage, could reduce
¢brotic scarring consequent to such damage [3].
A considerable body of evidence has accumulated
in recent years to support the hypothesis that oxida-
tive stress may play a major role in the pathogenesis
of both acute and chronic liver injury. Although a
causal relationship between oxidative stress and he-
patocellular injury still remains a matter of debate
[16], in vitro experiments have demonstrated that
malondialdehyde, a product of lipid peroxidation
and therefore of oxidative stress, can cause cyto-
pathic changes and trigger collagen gene transcrip-
tion [17]. Drugs with antioxidant properties may
minimise acute hepatocellular damage and ¢brosis.
Preliminary studies suggest that colchicine may
have such properties [18] but few studies have ex-
plored this hypothesis in depth.
The present study examines the protective e¡ect of
colchicine pretreatment in an acute CCl4 rat model,
in which liver injury is predominantly mediated by
oxidative stress, examining both pro- and antioxi-
dant processes. With this multifaceted approach we
have sought to obtain an improved insight into the
pathogenesis of oxidative injury in hepatic and extra-
hepatic tissues and the e¡ects of colchicine treatment.
We have also examined the anti¢brotic properties
of colchicine using two chronic CCl4 administration
schedules: ¢rst, co-treatment with colchicine during
induction of cirrhosis by CCl4 over 10 weeks and
second, a long term (12 month) treatment regime in
which colchicine was administered only after cirrho-
sis had been established and further challenges with
CCl4 had been discontinued. The long term e¡ects of
colchicine on fully established cirrhosis in rats have
not been investigated previously and may be of con-
siderable clinical signi¢cance.
The aims of this study are twofold: (a) to examine
the antioxidant potential of colchicine in limiting
CCl4 mediated injury and (b) to examine the anti¢-
brotic e¡ects of colchicine in the liver, both during
development of cirrhosis and after it has fully devel-
oped.
2. Materials and methods
2.1. Animal models
To minimise heterogeneity we have used the Lewis
strain rat, which is genetically homogenous. Male
rats, 150^200 g initial weight, supplied by Charles
River UK (Cambridge, UK), were used throughout
the study. The rats were housed in cages in groups of
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4^5, fed on standard Beekay diet with ad libitum
access to drinking water. Those rats destined to re-
ceive CCl4 also received phenobarbitone in drinking
water (350 mg/l) to induce the hepatic cytochrome
P-450 enzyme system. The project was licensed by
the Home O⁄ce under the Animals (Scienti¢c pro-
cedures) Act 1986.
2.1.1. Acute CCl4 model
The e¡ect of colchicine on oxidant stress was ex-
amined following pretreatment with the drug in an
acute CCl4 rat model. Rats were pretreated (by gav-
age) with either colchicine 100 Wg/day or water for
7 days. On the ¢nal day, 30 min after colchicine/
water administration, a single bolus dose of 3 ml of
CCl4 in liquid para⁄n (1:1) or 1.5 ml of liquid par-
a⁄n was administered by the intragastric route using
a metal gavage tube. Rats were sacri¢ced 3 h later.
Time course experiments (not shown) demonstrated
that liver MDA levels reached a maximum at 3 h
after CCl4 administration. This was in agreement
with other published data, and therefore this time
point was used for sampling in all subsequent experi-
ments. Each study group consisted of nine rats:
group 1 (control) ^ water for 7 days, followed by
bolus administration of liquid para⁄n only; group
2 (control plus colchicine) ^ colchicine for 7 days,
followed by bolus administration of liquid para⁄n
only; group 3: (CCl4) ^ water for 7 days, followed
by bolus administration of CCl4 ; group 4 (CCl4 plus
colchicine) ^ colchicine for 7 days, followed by bolus
administration of CCl4.
2.1.2. Cirrhosis model
To examine the anti¢brotic properties of colchicine
in vivo, cirrhosis was induced by repeated adminis-
tration of CCl4 (ten weekly doses), according to the
protocol suggested by Proctor [19]. In our study,
however, rats were not anaesthetised during the gav-
age procedures; this reduced the incidence of hypo-
tension and hypoxia, and greatly reduced mortality.
Study groups were as follows: group 1: CCl4 ad-
ministration for 10 weeks ^ eight rats were sacri¢ced
1 week after completion of treatment; group 2: CCl4
administration for 10 weeks with co-administration
of colchicine (100 Wg/day) ^ ten rats were sacri¢ced
1 week after completion of treatment; group 3: CCl4
administration for 10 weeks ^ four rats were sacri-
¢ced after a further 52 week period; group 4: CCl4
administration for 10 weeks with subsequent main-
tenance treatment with colchicine (1 mg/l in drinking
water; corresponding to a dose of 20^30 Wg/day) ^
six rats were sacri¢ced after a further 52 week period.
No deaths occurred in groups 3 and 4 between
10 weeks and sacri¢ce. The physical condition of
the animals after the induction of cirrhosis made it
impossible for us to obtain blood samples or baseline
liver biopsies before colchicine treatment com-
menced, but all our previous studies have shown
that animals receiving ten weekly doses of CCl4 de-
veloped cirrhosis without exception (data not
shown).
2.1.3. Specimen procedures
Blood was collected by intracardiac puncture
under terminal halothane anaesthesia. Tissue samples
for histology were collected in Bouin’s liquid and
those for biochemical estimation were snap-frozen
in liquid nitrogen and stored at 370‡C. Urine sam-
ples were collected from the bladder post-mortem.
2.2. Histological analysis
To minimise variation due to sampling error, 6^8
sections from representative areas of the liver were
examined. Sections of Bouin’s ¢xed, formalin em-
bedded liver were cut at 4 Wm and stained with hae-
matoxylin and eosin, and picrosirius red. Histologi-
cal scoring of ¢brosis was carried out by a single
histopathologist blinded to the identity of the sam-
ples. Severity of ¢brosis was scored according to
Ishak’s Modi¢cation of the Histopathology Activity
Index (HAI), a score of 6 indicating cirrhosis [20].
2.3. Biochemical analysis
In this study a number of oxidant and antioxidant
markers have been employed. Most studies use a
single marker of oxidative stress, most commonly
serum or tissue MDA levels, as measured by the
thiobarbituric acid reactive substances (TBARS) as-
say. To increase sensitivity and to investigate new
methods, we have included two novel markers of
lipid peroxidation. Our data on TBARS are sup-
ported by an improved £uorimetric assay for MDA
in whole serum. Urinary levels of F2-isoprostane, a
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peroxidation product of arachidonic acid, provide an
additional measure of oxidative stress. Tissue gluta-
thione (GSH) levels and serum antioxidant levels
were measured. This approach allows quantitation
of both pro- and antioxidant processes.
2.3.1. Urinary 8-isoprostane
Small volumes of rat urine (12^100 Wl) were di-
luted to 0.5 ml with ultrapure water. 10 Wl
[3H]prostaglandin F2K (NEN, Boston, MA, USA)
containing 20 000 dpm was added to estimate recov-
ery. Solid phase extraction was carried out [21] on
C18 BondElut (Varian, Harbor City, CA, USA). Ex-
tracts were reconstituted in 1 ml 0.1 M phosphate
bu¡er pH 7.4 containing 1% BSA. After taking
0.375 ml for 3H counting, 50 Wl aliquots were assayed
for 8-iso-PGF2K using an enzyme linked immunoas-
say kit (Cayman Chemicals, Ann Arbor, MI, USA).
Urinary creatinine was estimated using an alkaline
picrate solution [22].
2.3.2. Tissue and serum MDA
Lipid peroxides were determined as MDA by the
TBARS method. Tissue homogenates in 1 M sodium
acetate bu¡er (pH 3.5) containing 0.4% (w/v) sodium
dodecyl sulphate were incubated with 0.2% (w/v)
TBA at 95‡C for 60 min [23]. The red pigment gen-
erated was extracted with butan-1-ol and measured
£uorimetrically. 1,1,3,3-Tetraethoxypropane (Sigma,
Poole, Dorset, UK) was used as a standard. MDA
in serum was measured in the same way after precip-
itation of serum lipoproteins using a phosphotungstic
acid-sulphuric acid system that ensures removal of
interfering water-soluble substances [24]. As the
TBARS method proved relatively insensitive for
MDA measurement in acid precipitated serum, an
improved and more reproducible £uorimetric meth-
od using 1,3-diethyl-2-thiobarbituric acid (DETBA)
to measure MDA in whole serum was also used [25].
Tissue protein was estimated using the £uorescamine
assay [26].
2.3.3. Tissue GSH
This was measured using o-phthalaldehyde (Sig-
ma) as a £uorescent reagent [27].
2.3.4. Total antioxidant capacity
This was measured in whole serum by an enhanced
chemiluminescent technique [28]. A stable light out-
put was generated by mixing 200 Wl signal reagent
containing luminol plus enhancer and an oxidant
(Supersignal CL-HRP Substrate System, Pierce and
Warriner, Chester, UK), 2.3 ml water and 25 Wl of a
1/250 dilution of anti-mouse IgG horse radish per-
oxidase linked whole antibody from sheep (Sigma).
Addition of 50 Wl whole serum (diluted 1/10 with
distilled water) or Trolox standard (50 WM) (Aldrich,
Gillingham, Dorset, UK) resulted in depression of
the signal for a period of time proportional to the
antioxidant concentration. Results were expressed as
trolox equivalents, assuming a stoichiometric factor
of 2. Individual antioxidants were assayed by the
same method at suitable concentrations, which gave
a depression in the signal for a convenient time peri-
od (between 30 s and 4 min).
2.3.5. Liver enzyme markers
Serum AST, ALT and ALP were determined by
standard automated techniques in the Biochemistry
Department, Manchester Royal In¢rmary.
2.3.6. Biochemical markers of hepatic collagen
synthesis
Liver hydroxyproline levels were measured as an
index of total liver collagen content by Dr Gunzler,
Hoechst, Frankfurt, and serum type III procollagen
peptide (PIIINP), as an indicator of hepatic ¢bro-
genesis (new collagen synthesis), was measured by
Dr D. Schuppan, Freie Universita«t Berlin.
2.4. Statistical analysis
All data are expressed as medians with the inter-
quartile range. In the acute CCl4 model, di¡erences
between groups were assessed by the Mann-Whitney
U-test with P6 0.05 being considered statistically
signi¢cant. In the cirrhosis model, Fisher’s exact
test was used to compare groups 3 and 4.
3. Results
3.1. The e¡ect of pretreatment with colchicine on
acute CCl4 injury
Table 1 and Fig. 1 show the e¡ect of CCl4 and
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colchicine on markers of pro- and antioxidant pro-
cesses in the acute injury model. Comparison of the
two control groups demonstrated that colchicine pre-
treatment alone did not signi¢cantly a¡ect any of the
markers of oxidant stress measured in this study and,
perhaps more surprisingly, in view of its proposed
antioxidant properties, it did not signi¢cantly elevate
total serum antioxidant levels.
CCl4, as expected, produced marked changes in
markers of oxidant stress. Co-administration of col-
chicine modi¢ed some of these e¡ects. After a single
dose of CCl4, a 6-fold rise in urinary isoprostane
level was noted (Table 1 and Fig. 1a); colchicine
pretreatment did not prevent this rise. As shown in
the Fig. 1a, individual isoprostane levels were very
variable, to a greater extent than seen with tissue
MDA concentrations.
Increased tissue levels of MDA were noted in both
the liver and the kidney after CCl4 administration
(Fig. 1b,c). This elevation in the kidney was signi¢-
cantly inhibited by colchicine pretreatment. Levels of
MDA in the small intestine were una¡ected in all
groups.
Using the standard TBARS method, no change in
serum MDA levels was seen with either CCl4 or with
colchicine. However, when an alternative, improved,
£uorimetric DETBARS method was employed, se-
rum MDA levels were signi¢cantly reduced by
CCl4 treatment; this reduction was inhibited by col-
chicine pretreatment.
Levels of antioxidants were variably a¡ected. He-
patic GSH remained unchanged in all groups, but in
contrast, kidney GSH was signi¢cantly increased
after CCl4 administration; this was not prevented
by colchicine pretreatment. Total serum antioxidant
levels appeared to drop after CCl4 administration,
although the fall was not signi¢cant. However, col-
chicine pretreatment appears to inhibit this fall and
total antioxidant levels were signi¢cantly higher com-
pared to the CCl4 treated group.
Serum levels of all three enzymes (AST, ALT and
ALP), that re£ect acute hepatocellular injury, were
elevated after a single administration of CCl4 ; col-
chicine did not prevent this.
3.2. Auxiliary co-administration and long term
colchicine studies
Liver histopathology ¢brosis scores for both stud-
ies are shown in Table 2. Colchicine co-administra-
tion did not prevent the development of cirrhosis:
after ten weekly doses, all eight rats receiving CCl4,
and nine of the ten rats receiving CCl4 plus colchi-
cine, developed cirrhosis.
However, long term administration of colchicine
to rats already rendered cirrhotic produced a signi¢-
Table 1
Pretreatment with colchicine in acute CCl4 injury: markers of lipid peroxidation, antioxidant status and hepatic injury
Assay Source Control Control+colchicine CCl4 CCl4+colchicine
8-Isoprostane (ng/g creatinine) urine 1.71 (0.22^2.24) 0.49 (0.27^1.03) 10.01* (8.29^12.58) 15.37** (12.57^17.02)
MDA (Wmoles/g protein) liver 1.19 (1.16^1.21) 1.30 (1.13^1.39) 1.45* (1.40^1.57) 1.40** (1.34^1.53)
MDA (Wmoles/g protein) kidney 0.89 (0.83^0.94) 0.89 (0.80^0.93) 1.63* (1.50^1.65) 1.39**;*** (1.33^1.53)
MDA (Wmoles/g protein) small
intestine
0.41 (0.36^0.54) 0.43 (0.39^0.50) 0.47 (0.44^0.56) 0.48 (0.42^0.53)
MDA (TBARS) (Wmoles/l) serum 3.08 (3.06^3.22) 3.37 (2.99^3.41) 3.09 (2.89^3.22) 3.26 (3.12^3.50)
MDA (DETBARS) (Wmoles/l) serum 12.11 (9.21^14.98) 11.31 (10.40^11.92) 7.58* (7.29^8.82) 9.16**;*** (8.43^9.95)
GSH (Wg/g wet weight) liver 1.23 (1.08^1.34) 1.16 (1.08^1.24) 1.21 (1.08^1.31) 1.07 (1.02^1.16)
GSH (Wg/g wet weight) kidney 0.087 (0.085^0.091) 0.081 (0.068^0.092) 0.12* (0.11^0.13) 0.12** (0.11^0.14)
Total antioxidant (Wmoles/l
trolox)
serum 533.6 (492.5^580.2) 622.0 (534.1^773.2) 498.4 (488.6^524.4) 583.1*** (545.5^605.0)
ALP (U/l) serum 593.0 (554.5^619.5) 580.0 (558.0^653.3) 673.0* (664.0^696.5) 707.0** (677.5^783.0)
AST (U/l) serum 118.0 (98.3^147.5) 83.0 (81.8^104.8) 238.5* (221.0^268.0) 292.0** (214.5^356.3)
ALT (U/l) serum 42.0 (39.0^48.0) 46.0 (38.3^50.3) 132.5* (101.5^158.0) 161.0** (119.5^209.0)
Signi¢cant values (P6 0.05) indicated by * (CCl4 vs. control), ** (CCl4+colchicine vs. control+colchicine) and *** (CCl4+colchicine
vs. CCl4).
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cant attenuation of ¢brosis. Four of the ten rats in
which cirrhosis had been induced received no further
treatment. As expected, all four remained cirrhotic
after 12 months (Fig. 2A). Their liver histology dem-
onstrated persistence of nodular architecture with ¢-
brous septa, which was evident in both reticulin (not
shown) and picrosirius red stained sections. In con-
trast, histological regression of cirrhosis was noted
(Fig. 2B) in all six rats receiving colchicine in drink-
ing water during the 12 month follow up period;
histological sections demonstrated very little ¢brosis,
mostly septal. Cirrhotic nodules were restricted to
focal areas and the overall picture suggested histo-
logical regression in all colchicine treated animals.
Their histological activity indices were 5 or less, in-
dividual scores being 2, 3, 3, 4, 4, and 5 respectively
(P = 0.005, by Fisher’s exact test compared to the
untreated group).
After 10 weeks of CCl4 administration, hepatic
hydroxyproline levels had increased 5-fold compared
to controls (control 156.7, cirrhotic 789.9 Wg/g liver,
P = 0.001). Following 12 months of colchicine treat-
ment, levels had dropped signi¢cantly (P = 0.041) to
475.7 Wg/g liver but were still higher than baseline
values (P = 0.001). PIIINP levels were higher follow-
ing 10 weeks of CCl4 administration but the increase
was not signi¢cant (control 7.00, treated 10.55 Wg/l).
Following 12 months of colchicine treatment levels
had fallen to 6.10 Wg/l but again this di¡erence was
not signi¢cant.
3.3. Antioxidant properties of colchicine in vitro
To obtain some estimate of the relative value of
colchicine as an antioxidant, the antioxidant proper-
Table 2
Co-administration of colchicine and long term treatment with
colchicine in the cirrhosis rat model
CCl4 CCl4+colchicine
Co-administration 8/8 9/10
Long term treatment 4/4 0/6*
The ¢gures indicate the number of animals with a liver histo-
pathology index of 6 (cirrhosis) compared to the total number
of animals in each group.
Signi¢cant value (P = 0.005) indicated by * (CCl4+colchicine vs.
CCl4 in long term treatment group).
Fig. 1. E¡ect of pretreatment with colchicine on acute CCl4 in-
jury: key markers of oxidant stress (a, control; b, CCl4
treated). Levels of signi¢cance are indicated.
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ties of some known plasma constituents were as-
sessed by an enhanced chemiluminescence technique
and compared with colchicine as shown in Table 3.
In agreement with other studies [28], ascorbic acid
and uric acid, the two major water-soluble antioxi-
dants in serum, produced almost complete suppres-
sion of chemiluminescence followed by rapid recov-
ery to give a square wave appearance similar to the
trolox standard. Trolox, ascorbic acid and uric acid
appeared to show an approx. 1:1 stoichiometric
equivalence. In contrast, albumin, bilirubin and
GSH showed kinetics of chemiluminescence emission
more characteristic of sulphydryl containing com-
pounds. Typically, these compounds produce signi¢-
Fig. 2. E¡ect of long term colchicine administration on histological regression of cirrhosis. 4 Wm liver sections were stained with hae-
matoxylin and eosin, and picrosirius red; original magni¢cation 150U. (A) CCl4 for 10 weeks, no subsequent treatment for 52 weeks.
(B) CCl4 for 10 weeks, colchicine treatment for 52 weeks (see Section 2).
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cant but not total suppression of the reaction even at
very high concentrations, with gradual recovery of
chemiluminescence. The inhibition produced by col-
chicine was of the second, sulphydryl type. It dem-
onstrated very weak antioxidant properties, even at a
high millimolar concentration. It is very unlikely that
such high concentrations would be achieved in vivo.
4. Discussion
This study has, for the ¢rst time, examined the
di¡erent facets of oxidative stress induced in the rat
by CCl4 liver injury and o¡ers new insights into the
mechanisms by which colchicine may be of bene¢t.
This improved understanding may lead to renewed
interest in the use of colchicine in chronic liver dis-
ease.
Oxidant damage produced by acute CCl4 injury
was re£ected by changes in a number of the markers
used. The increase in hepatic MDA seen in our ex-
periments was signi¢cant but modest compared to
that seen in some previous studies [2]. This may be
because whole liver homogenate was used for MDA
assessment rather than a puri¢ed microsomal frac-
tion. Alternatively, the smaller changes seen may be
a result of the time course of MDA production and
sampling at a sub-optimal time in our system. It is
interesting that there was no rise in small intestinal
MDA despite the proximity of the mucosa to high
concentrations of CCl4 in the gut lumen. This may
be related to a minimal breakdown of CCl4 within
the intestinal wall due to a lack of speci¢c cyto-
chrome P-450 enzymes. Also surprising was the ¢nd-
ing that the most signi¢cant rise in tissue MDA levels
was seen in the kidney rather than the liver: two
possible explanations must be considered. First,
MDA production in the kidney may be endogenous,
arising from oxidant damage produced by CCl4 es-
caping ¢rst pass metabolism in the liver. Exposure to
CCl4, regardless of the route of administration, is
well known to a¡ect most organs of the body. Alter-
natively, the high levels of MDA seen in the kidney
may have arisen as a result of trapping of MDA-
lipoprotein complexes within the kidney.
Serum MDA levels were too low for reliable esti-
mation by the TBARS method. In addition, many
other substances, circulating in the serum, are known
to interfere in the colorimetric assay for MDA, thus
lowering speci¢city. These problems may account for
the sparsity of data currently available from animal
experiments on serum MDA. In this study, we have
seen an unusual pattern of serum MDA changes.
Three hours after acute CCl4 injury, despite an in-
crease in tissue MDA levels, serum MDA levels fell,
but only when measured by the DETBARS method.
However, such a fall in serum MDA levels has also
been consistently observed in our previous experi-
ments (unpublished data). We propose that the
drop in serum MDA at 3 h found in our experiments
is due to an exit block of lipoprotein containing lipid
peroxidation products from the hepatocytes. CCl4
administration in the rat damages the Golgi appara-
tus; this, in turn, adversely a¡ects packaging and
release of protein from the hepatocyte. Some pro-
teins such as lipoprotein and albumin are more af-
fected than others [29].
We have used urinary isoprostane levels as a
marker of lipid peroxidation. The isoprostanes are
a family of eicosanoids of non-enzymatic origin pro-
duced by the random oxidation of tissue phospholip-
ids by oxygen radicals and are subsequently released
in free form by the action of phospholipase [30].
They appear in the plasma and urine under normal
conditions but are elevated by oxidative stress. 8-iso-
prostane is a peroxidation product of arachidonic
acid. This fatty acid is unusually sensitive to perox-
idation because of its multiple double bonds, and
urinary levels appear to o¡er a sensitive new marker
of oxidant stress. Increased serum isoprostane levels
have been detected in both CCl4 and alcoholic rat
models [31]. In the latter group, serum isoprostane
levels correlated strongly with hepatic conjugated di-
ene levels and histological activity. In addition, bili-
Table 3
Individual antioxidants assayed in vitro by the enhanced chemi-
luminescent antioxidant assay (see Section 2)
Antioxidant Concentration Trolox (Wmoles/l)
Trolox 50 WM ^
Albumin 227 WM 40.3
Ascorbic acid 50 WM 42.8
Bilirubin 17 WM 27.7
Colchicine 50 mM 7.8
GSH 81 WM 41.8
Uric acid 50 WM 53.7
BBADIS 61973 23-10-00
D. Das et al. / Biochimica et Biophysica Acta 1502 (2000) 351^362358
ary isoprostane excretion has been detected in the
bile duct ligated rat model [32] but there are, as
yet, no data on urinary isoprostane in a CCl4 rat
model. In our study, grossly elevated levels were
seen in urine following CCl4 injury, although consid-
erable variation was found. Since urinary isoprostane
levels were expressed as a ratio compared to urinary
creatinine levels, a variation in the rate of urinary
creatinine excretion or in the amount of residual
urine present in the bladder prior to administration
of CCl4, would account for the wide variation in
urinary isoprostane results.
The body’s antioxidant defences normally undergo
consumptive depletion following oxidative injury.
However, in the period immediately following CCl4
challenge, GSH turnover may be accelerated brie£y,
as part of the natural hepatocyte protective mecha-
nism [33]. This may explain why no drop in hepatic
GSH levels was noted and why kidney GSH levels
rose signi¢cantly. A similar e¡ect on liver GSH levels
has been noted previously in alcohol fed rats [34] and
bile duct ligated rats [35].
The e¡ect of colchicine on the parameters a¡ected
by CCl4 treatment was variable. Colchicine did not
a¡ect the observed rise in urinary isoprostane levels
but ameliorated the rise in kidney MDA levels and
the fall in serum DETBARS concentration. Pretreat-
ment with colchicine does not appear to protect
against CCl4 injury. The previous ¢nding [13] that
colchicine may produce a bene¢cial e¡ect by reduc-
ing cytochrome P-450 levels may be countered in our
system by the presence of phenobarbitone in the
drinking water. This will raise cytochrome P-450 lev-
els and thus negate any possible decrease in free rad-
ical generation by this mechanism. Very few data are
available from previous studies for comparison with
our data and they are almost exclusively related to
hepatic MDA levels. A 2^3-fold rise in hepatic MDA
levels was noted after CCl4 and galactosamine injury
[2,5]. Preadministration of colchicine ameliorated
such changes in a dose dependent manner. However,
since estimations were carried out in microsomal ex-
tracts rather than whole liver homogenates, true
comparison with our results cannot be made.
The luminescence assay employed in this study to
measure total serum antioxidant levels provides a
global view of the body’s antioxidant reserves, in
both the aqueous and lipid phases. It is maintained
by a complex array of factors, such as antioxidant
turnover rates in the tissues, recycling of ascorbic
acid and tocopherol, and production of bilirubin
and urate. In this study, although no signi¢cant fall
in serum antioxidant levels was noted within 3 h of
acute CCl4 injury, colchicine pretreatment did en-
hance antioxidant levels to a signi¢cant degree in
the colchicine-CCl4 group. We initially proposed
that the presence of colchicine in serum might di-
rectly enhance total antioxidant capacity; this hy-
pothesis was not supported by subsequent in vitro
experiments using the luminescence assay, which
demonstrated that colchicine has only weak antioxi-
dant properties, even at high and supraphysiological
concentrations.
Results from our study are complementary to the
general view that colchicine has poor direct antioxi-
dant properties. Its hepatoprotective e¡ects are prob-
ably mediated by a ‘membrane stabilisation e¡ect’, as
suggested by Rojkind [11]. In CCl4 induced injury,
the brunt of the damage falls on hepatocellular mem-
branes. Relative loss of phospholipid moieties results
in an alteration of the membrane cholesterol-phos-
pholipid ratio; as a result, the cell membrane loses its
£uidity, leading to abnormal transmembrane signal
transmission and ultimately to cell injury, ¢brosis or
death. Colchicine treatment has been shown to cor-
rect these membrane changes both in vivo and in
vitro [12,14]. Several other hepatoprotective mecha-
nisms have been proposed, including restoration of
depleted glycogen stores and reduction of ¢brosis
[11]. In the bile duct ligation model, Cedillo et al.
[36] demonstrated bene¢cial e¡ects of colchicine
and its chemical analogue trimethylcolchicinic acid
on plasma membrane and serum enzyme activities
as well as hepatic glycogen content, although the
bile duct ligation model is not equivalent to our
acute, single dose CCl4 model. Trimethylcolchicinic
acid is as e¡ective as colchicine, but does not bind to
tubulin, possibly explaining the reduced level of side
e¡ects and thus higher tolerance in this rat model
[37,38].
The anti¢brotic e¡ects of colchicine, in the short
term, have been demonstrated in both CCl4 treated
and bile duct ligated rat models. However, in our
study, co-administration of colchicine with CCl4
did not prevent development of cirrhosis, even
though the drug was used at higher doses than in
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previous experiments [3,37]. Our animals tolerated
colchicine in a daily dose of 100 Wg without any
additional notable weight loss or mortality. This
could be because of di¡erences in strain, initial
weight and nature of the liver injury. In recent years,
increased tolerance to drugs such as certain types of
chemotherapeutics and colchicine, have been related
to expression of a multiple drug resistance (MDR)
gene on the canalicular membrane of the hepatocyte.
Such expression facilitates elimination of drugs into
bile and thus diminishes their therapeutic activity.
Expression of an MDR gene has been reported in
colchicine treated Wistar rats, a close variant of the
Lewis strain [39].
Our ¢ndings support Cedillo’s observations that
colchicine treatment during induction of cirrhosis
with CCl4 does not prevent progression to cirrhosis
[36]. In Rojkind’s original study [3], reference was
made to improvement of hepatic ¢brosis, but details
of staining and histological evaluation are not avail-
able. Our observations contrast with the results of
studies using the bile duct ligated rat model, where
administration of either colchicine or trimethylcolchi-
cinic acid resulted in a slower histological and ultra-
structural deterioration at 4 and 8 weeks after bile
duct ligation [37,38]. This di¡erence in our ¢ndings
may arise from the pathogenesis of liver damage in
these distinct models, the CCl4 model probably act-
ing by a more direct free radical mechanism.
Our study is the ¢rst to examine the value of long
term (12 months) colchicine treatment, commencing
after discontinuation of CCl4 administration, in an
animal which is cirrhotic: this is a situation which is
much closer to that normally seen in clinical practice.
The histological changes seen in CCl4 induced cirrho-
sis are notoriously heterogeneous and di⁄cult to in-
terpret as the response of individual animals is very
variable. There is also some contention as to the
reversibility of histological cirrhosis in the CCl4 rat
model [40]. Previous studies have shown that sponta-
neous histological regression of ¢brosis occurs only
when the period of CCl4 administration is less than 4
weeks [41]. Hepatic stellate cells, activated by oxidant
stress, overproduce extracellular matrix components
and tissue inhibitors of metalloproteinases (TIMPs).
These TIMPs inhibit collagenases (matrix metallo-
proteinase) which normally degrade collagen. If oxi-
dant stress is diminished, activated hepatic stellate
cells are removed by apoptosis. The resulting reduc-
tion in TIMP levels produces an increase in collage-
nase levels which leads to degradation of ¢brous tis-
sue. However, if administration of CCl4 is continued
to the point where cirrhosis has become fully estab-
lished, such spontaneous regression is no longer pos-
sible [40,41]. By this point, collagen ¢brils have de-
veloped extensive cross-links formed by both tissue
transglutaminase and lysyl oxidase pathways, reduc-
ing their susceptibility to spontaneous collagenolysis,
a process that operates in tandem with collagen dep-
osition. Previous studies have shown that fully estab-
lished cirrhosis does not reverse spontaneously in 6
months [42] and our control group of four rats
showed no reversion even after a year.
However, in our study, when low dose colchicine
was administered for 12 months, a reduction in ¢-
brosis and reversal of cirrhosis (based on the Ishak
scoring system) was clearly seen in all six rats. These
histological observations are supported by biochem-
ical data on liver hydroxyproline levels which showed
a massive increase (5-fold) after CCl4 administration,
followed by a signi¢cant fall (but not to baseline
levels) after 12 months of colchicine treatment. Mea-
surement of serum PIIINP was not found to be of
value in this study. PIIINP re£ects acute changes in
the rate of production of new collagen and may well
not correlate with histological data, which re£ects
chronic cumulative e¡ects. The di⁄culty and expense
of carrying out this type of long term study restricted
the number of animals employed, but these promis-
ing ¢ndings suggest that a larger scale study may be
of value.
The mechanism by which this anti¢brotic e¡ect of
colchicine operates in the cirrhotic liver remains to
be established. The collagen pool, though apparently
inert, is in a state of constant turnover, primarily
aimed at remodelling scars, a process which is vital
to tissues during recovery from injury, e.g., the heart
muscle after myocardial infarction or the uterus after
parturition. The rate of collagen turnover is con-
trolled by a number of factors as discussed above,
but it is not known whether colchicine can modulate
any of these factors. Previous studies have shown
that collagen turnover is a¡ected early in the evolu-
tion of cirrhosis in the CCl4 rat model leading to
collagen accumulation which can be prevented, to
some extent, by zinc co-administration [43].
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Although similar data are not available for colchi-
cine, this drug is known to enhance collagenase ac-
tivity in other animal models [44] and in vitro [45]. In
at least two clinical studies, long term use of colchi-
cine has been shown to be of bene¢t: either slowing
histological progression [10] or, in the Kershenobich
study [7], reversing histological cirrhosis in a minor-
ity of cases. We therefore hypothesise that long term
colchicine administration may trigger increased col-
lagenase activity in cirrhotic rats, leading to degra-
dation of preformed collagen and resulting in the
histological improvement and regression of cirrhosis
seen in our ¢ndings. Future studies will involve de-
termination of the activity and expression of matrix
metalloproteinases and TIMPs.
In summary, colchicine pretreatment has been
shown to confer very little protection against lipid
peroxidation after acute CCl4 injury in rats. Its role
as an antioxidant is, at best, minimal and the drug
was found to be ine¡ective in halting the pace of
histological deterioration during chronic CCl4 injury.
In contrast, prolonged administration of low dose
colchicine resulted in histological regression of cir-
rhosis, an observation that may have considerable
clinical relevance.
References
[1] R.F. Diegelmann, B. Peterkofsky, Proc. Natl. Acad. Sci.
USA 69 (1972) 892^896.
[2] M. Mourelle, C. Villalon, J.L. Amezcua, J. Hepatol. 6 (1988)
337^342.
[3] M. Rojkind, D. Kershenobich, Biochim. Biophys. Acta 378
(1975) 415^423.
[4] H. Dashti, B. Jeppson, I. Hagerstrand, B. Hultberg, U. Sri-
nivas, M. Abdulla, S. Bengmark, Eur. Surg. Res. 21 (1989)
83^91.
[5] M. Mourelle, M.A. Meza, J. Hepatol. 8 (1989) 165^172.
[6] J.L. Poo, G. Feldman, A. Moreau, C. Gaudin, D. Lebrec,
J. Hepatol. 19 (1993) 90^94.
[7] D. Kershenobich, F. Vargas, G. Garcia-Tsao, R. Perez Tam-
ayo, M. Gent, M. Rojkind, New Engl. J. Med. 318 (1988)
1709^1713.
[8] T.W. Warnes, A. Smith, F.I. Lee, N.Y. Haboubi, P.J. John-
son, L. Hunt, J. Hepatol. 5 (1987) 1^7.
[9] R. Olsson, U. Broome, A. Danielsson, I. Ha«gerstrand, G.
Ja«rnerot, L. Lo«o«f, H. Prytz, B.O. Ryde¤n, S. Wallerstedt,
Gastroenterology 108 (1995) 1199^1203.
[10] T.W. Warnes, Aliment. Pharmacol. Ther. 5 (1991) 321^
329.
[11] M. Rojkind, Pharmacol. Ther. 53 (1992) 81^104.
[12] P. Yahuaca, A. Amaya, M. Rojkind, M. Mourelle, Lab.
Invest. 53 (1985) 541^545.
[13] P. Muriel, M. Martinez, M. Mourelle, Hepatology 20 (1994)
378A.
[14] J.A. Solis-Herruzo, M. De Gando, M.P. Ferrer, I. Hernan-
dez Mun‹oz, B. Fernandez-Boya, M.P. De la Torre, M.T.
Mun‹oz-Yague, Gut 34 (1993) 1438^1442.
[15] M. Mourelle, M. Rojkind, B. Rubaclava, Toxicology 21
(1981) 213^222.
[16] D.L. Tribble, Y.A. Tak, D.P. Jones, Hepatology 7 (1987)
377^387.
[17] P. Bedossa, K. Houglum, C. Trautwein, A. Holstege, M.
Chojkier, Hepatology 19 (1994) 1262^1271.
[18] M. Rojkind, M. Mourelle, D. Kershenobich, in: P.D. Berk
(Ed.), Myelo¢brosis and the Biology of Connective Tissue,
Liss, New York, 1984, pp. 475^489.
[19] E. Proctor, K. Chatambra, Gastroenterology 83 (1982)
1183^1190.
[20] K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote,
F. Gudat, H. Denk, V. Desmet, G. Korb, R.N. MacSween
et al., J. Hepatol. 22 (1995) 696^699.
[21] A. Barden, L.J. Beilin, J. Ritchie, K.D. Croft, B.N. Walters,
C.A. Michael, Clin. Sci. 91 (1996) 711^718.
[22] J. Brod, J.H. Sirota, J. Clin. Invest. 27 (1948) 645^654.
[23] H. Ohkawa, N. Ohishi, K. Yagi, Anal. Biochem. 95 (1979)
351^358.
[24] K. Yagi, Biochem. Med. 15 (1976) 212^216.
[25] M. Conti, P.C. Morand, P. Levillain, A. Lemonnier, Clin.
Chem. 37 (1991) 1273^1275.
[26] S. Udenfriend, S. Stein, P. Bohlen, W. Dairman, W. Leim-
gruber, M. Weigele, Science 178 (1972) 871^872.
[27] P.J. Hissin, R. Hilf, Anal. Biochem. 76 (1976) 214^226.
[28] T.P. Whitehead, G.H.G. Thorpe, S.R.J. Maxwell, Anal.
Chim. Acta 266 (1992) 265^277.
[29] G. Poli, E. Chiarpotto, E. Albano, D. Cottalasso, G. Nanni,
U.M. Marinari, A.M. Bassi, M.U. Dianzani, Life Sci. 36
(1985) 533^539.
[30] J.A. Awad, J.D. Morrow, K. Takahashi, L.J. Roberts,
J. Biol. Chem. 268 (1993) 4161^4169.
[31] A.A. Nanji, S. Khwaja, S.R. Tahan, S.M. Sadrzadeh,
J. Pharmacol. Exp. Ther. 269 (1994) 1280^1285.
[32] J.A. Awad, J.D. Morrow, Hepatology 22 (1995) 962^
968.
[33] L.D. Deleve, N. Kaplowitz, Semin. Liver Dis. 10 (1990) 251^
266.
[34] J.P. Teare, S.M. Green¢eld, D. Watson, N.A. Punchard, N.
Miller, C.A. Rice-Evans, R.P. Thompson, Gut 35 (1994)
1644^1647.
[35] V. Baron, P. Muriel, Biochim. Biophys. Acta 1472 (1999)
173^180.
[36] A. Cedillo, M. Mourelle, P. Muriel, Pharmacol. Toxicol. 79
(1996) 241^246.
[37] V. Castro, P. Muriel, J. Appl. Toxicol. 16 (1996) 269^275.
[38] P. Muriel, P.U. Ostoa-Saloma, J.A. Reyes-Espara, L. Rodri-
guez-Fragoso, J. Appl. Toxicol. 17 (1997) 145^151.
BBADIS 61973 23-10-00
D. Das et al. / Biochimica et Biophysica Acta 1502 (2000) 351^362 361
[39] V. Vollrath, A.M. Wielandt, C. Acuna, I. Duarte, L. An-
drade, J. Chianale, J. Hepatol. 21 (1994) 754^763.
[40] R.P. Tamayo, Hepatology 3 (1983) 112^120.
[41] R.C. Benyon, J.P. Iredale, Gut 46 (2000) 443^446.
[42] A. Fischer-Nielson, H.E. Poulsen, B.A. Hansen, E. Hage, S.
Keiding, J. Hepatol. 12 (1991) 110^117.
[43] A. Gime¤nez, A. Pare¤s, S. Alie¤, J. Camps, R. Deulofeu, J.
Caballer|¤a, J. Rode¤s, J. Hepatol. 21 (1994) 292^298.
[44] N. Itoh, M. Kasamatsu, S. Onosaka, N. Muto, K. Tanaka,
Toxicology 116 (1997) 201^209.
[45] E.D. Harris, S.M. Krane, Arthritis Rheum. 14 (1971) 669^
683.
BBADIS 61973 23-10-00
D. Das et al. / Biochimica et Biophysica Acta 1502 (2000) 351^362362
